-Richard B Rothman Researcher Activity Profile

Research Author Detailed Information 

Richard B Rothman Publication Rate By Year

Richard B Rothman has published 5 paper(s) in 2006, 18 paper(s) in 2007, 3 paper(s) in 2008, for a total of 26 research publications in total.

Richard B Rb Rothman Author Information

LAST NAME: rothman

FIRST NAME: Richard B

INITIALS: rb

AFFILIATION:

Papers

Richard B Rothman's Publication Record

1. Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists. Year Published: 2007
Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892-0815, USA.
2. Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. Year Published: 2007
Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD 21224, USA. rrothman@mail.nih.gov
3. Dual dopamine-5-HT releasers: potential treatment agents for cocaine addiction. Year Published: 2006
Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, PO Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA. rrothman@mail.nih.gov
4. DAT/SERT selectivity of flexible GBR 12909 analogs modeled using 3D-QSAR methods. Year Published: 2006
Department of Chemistry and Environmental Science, New Jersey Institute of Technology, University Heights, Newark, NJ 07102, USA.
5. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Year Published: 2007
Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, Baltimore, Maryland 21224, USA.
6. Salvinorin A: allosteric interactions at the mu-opioid receptor. Year Published: 2007
Clinical Psychopharmacology Section, Intramural Research Program, National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA. rrothman@mail.nih.gov
7. Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys. Year Published: 2007
Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, Belmont, MA 02478-9106, USA. negus@mclean.harvard.edu
8. An opioid agonist that does not induce micro-opioid receptor--arrestin interactions or receptor internalization. Year Published: 2007
Department of Pharmacology, the Ohio State University College of Medicine, 333 W 10th Avenue, 5184A Graves Hall, Columbus, OH 43210, USA.
9. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. Year Published: 2007
Division of Medicinal & Natural Products Chemistry, College of Pharmacy, The University of Iowa, Iowa City, Iowa 52242, USA.
10. Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series. Year Published: 2007
Drug Design and Synthesis Section, Chemical Biology Research Branch, National Institute on Drug Abuse, National Institutes of Health, DHHS, Bethesda, MD 20892, USA.
11. Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan. Year Published: 2007
Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, P.O. Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA.
12. Methamphetamine and idiopathic pulmonary arterial hypertension: role of the serotonin transporter. Year Published: 2007
13. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: exploration of the 1-position. Year Published: 2007
Holden Laboratories, Carmel, CA 93923, USA.
14. Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan. Year Published: 2007
Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, P.O. Box 5180, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA.
15. Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Year Published: 2007
Clinical Psychopharmacology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 333 Cassell Dr., Baltimore, MD 21224, USA.
16. Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. Year Published: 2008
Clinical Psychopharmacology, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Heath and Human Services, 5500 Nathan Shock Dr., Baltimore, MD 21224, USA.
17. Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Year Published: 2007
Clinical Psychopharmacology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 333 Cassell Dr., Baltimore, MD 21224, USA.
18. Chronic fenfluramine administration increases plasma serotonin (5-hydroxytryptamine) to nontoxic levels. Year Published: 2008
Clinical Psychopharmacology, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Heath and Human Services, 5500 Nathan Shock Dr., Baltimore, MD 21224, USA.
19. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A. Year Published: 2006
Division of Medicinal & Natural Products Chemistry, College of Pharmacy, The University of Iowa, Iowa City, Iowa 52242, USA.
20. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ring. Year Published: 2006
Division of Medicinal and Natural Products Chemistry, College of Pharmacy, The University of Iowa, Iowa City, IA 52242, USA.
21. Synthesis of salvinorin A analogues as opioid receptor probes. Year Published: 2006
Division of Medicinal & Natural Products Chemistry, College of Pharmacy, The University of Iowa, Iowa City, Iowa 52242, USA.
22. A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Year Published: 2007
Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, Baltimore, Maryland 21224, USA.
23. Salvinorin A: allosteric interactions at the mu-opioid receptor. Year Published: 2007
Clinical Psychopharmacology Section, Intramural Research Program, National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA. rrothman@mail.nih.gov
24. An opioid agonist that does not induce micro-opioid receptor--arrestin interactions or receptor internalization. Year Published: 2007
Department of Pharmacology, the Ohio State University College of Medicine, 333 W 10th Avenue, 5184A Graves Hall, Columbus, OH 43210, USA.
25. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. Year Published: 2007
Division of Medicinal & Natural Products Chemistry, College of Pharmacy, The University of Iowa, Iowa City, Iowa 52242, USA.
26. Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges. Year Published: 2008
Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 333 Cassell Drive, Suite 4500, Baltimore, MD 21224, USA.